Publication:
Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

dc.contributor.authorH. McManusen_US
dc.contributor.authorPck Lien_US
dc.contributor.authorD. Nolanen_US
dc.contributor.authorM. Blochen_US
dc.contributor.authorS. Kiertiburanakulen_US
dc.contributor.authorJ. Y. Choien_US
dc.contributor.authorB. Mulhallen_US
dc.contributor.authorK. Petoumenosen_US
dc.contributor.authorJ. Zhouen_US
dc.contributor.authorM. Lawen_US
dc.contributor.authorB. J. Brewen_US
dc.contributor.authorE. Wrighten_US
dc.contributor.otherKirby Instituteen_US
dc.contributor.otherQueen Elizabeth Hospital Hong Kongen_US
dc.contributor.otherRoyal Perth Hospitalen_US
dc.contributor.otherHoldsworth House General Practiceen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherYonsei University College of Medicineen_US
dc.contributor.otherUniversity of Sydney Faculty of Medicineen_US
dc.contributor.otherSt. Vincent's Hospital Sydneyen_US
dc.contributor.otherMonash Universityen_US
dc.date.accessioned2018-05-03T08:24:00Z
dc.date.available2018-05-03T08:24:00Z
dc.date.issued2011-11-01en_US
dc.description.abstractObjectives: The aim of the study was to determine whether combination antiretroviral therapy (cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is associated with increased survival benefit compared with non-neurocART. Methods: Prospective data were examined for HIV-positive patients in the Asia Pacific HIV Observational Database who had commenced cART. CPE rank was calculated using the 2010 rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more. Survival was analysed using Cox proportional hazards models with covariates updated at changes in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen. Sensitivity analyses were conducted to examine the robustness of analysis assumptions. Results: Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use was 0.89 (P=0.35) when data were stratified by cohort and adjusted for age, mode of HIV exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite endpoint of AIDS-defining illness or death (HR=0.93; P=0.61), baseline regimen as neurocART (HR=0.95; P=0.69), CPE category (P=0.71) and prior neurocART duration (P=0.16). No association between CD4 cell count and neurocART use was observed (P=0.52). Conclusions: Our findings do not show a significant overall survival benefit associated with neurocART compared with cART. The potential benefit associated with neurocART in terms of prevention of neurocognitive impairment did not translate into an improvement in overall survival in this population. These findings were limited by the low incidence of associated mortality. Further studies and more extensive data are needed to address these limitations. © 2011 British HIV Association.en_US
dc.identifier.citationHIV Medicine. Vol.12, No.10 (2011), 610-619en_US
dc.identifier.doi10.1111/j.1468-1293.2011.00938.xen_US
dc.identifier.issn14681293en_US
dc.identifier.issn14642662en_US
dc.identifier.other2-s2.0-80054840297en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/12255
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80054840297&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleDoes use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?en_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80054840297&origin=inwarden_US

Files

Collections